A mid-stage trial of 4D Molecular Therapeutics gene therapy for eye disease ... in the 12 months after administration. Two-thirds (63%) of the patients did not need any Eylea injections at all ...

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have ... (DME), and diabetic retinopathy (DR), after rejecting the drug in June due to quality ...

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved ...

Intravitreal anti-VEGF agents are linked to a slight increase in the risk for stroke in patients with age-related macular ...

Patients with prior treatment for diabetic macular edema (DME) may require more frequent dosing of aflibercept (Eylea), according to a subgroup analysis of the PHOTON trial presented at the recent ...

Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...